Citrulline as a marker for chemotherapy induced mucosal barrier injury in pediatric patients

Pediatric Blood and Cancer

Volumn 53, Issue 7, 2009, Pages 1188-1194

  Van Vliet, Michel J ^a   Tissing, Wim J E ^a   Rings, Edmond H H M ^a   Koetse, Harma A ^a   Stellaard, Frans ^a   Kamps, Willem A ^a   De Bont, Eveline S J M ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Cancer; Chemotherapy; Childhood; Laboratory tests; Mucositis

Indexed keywords

AMSACRINE; CITRULLINE; CYTARABINE; DAUNORUBICIN; DNA; ETOPOSIDE; INTERLEUKIN 8; MITOXANTRONE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CALGRANULIN; CARBOHYDRATE; DIAGNOSTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; AMINO ACID BLOOD LEVEL; ARTICLE; CANCER CHEMOTHERAPY; CELL LOSS; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DISEASE SEVERITY; DRUG MEGADOSE; ENTERITIS; FECES LEVEL; FEMALE; GOLD STANDARD; HUMAN; INTESTINE ABSORPTION; INTESTINE CELL; INTESTINE MUCOSA PERMEABILITY; LABORATORY TEST; MALE; MOUTH INFLAMMATION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; ACUTE DISEASE; BIOLOGICAL MODEL; BLOOD; CELL DEATH; CHEMICALLY INDUCED DISORDER; CHEMISTRY; CLINICAL TRIAL; FECES; INFANT; ISOLATION AND PURIFICATION; METABOLISM; MYELOID LEUKEMIA; PATHOLOGY; STOMATITIS;

ACUTE DISEASE; ADOLESCENT; AMSACRINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CARBOHYDRATES; CELL DEATH; CHILD; CHILD, PRESCHOOL; CITRULLINE; CYTARABINE; DAUNORUBICIN; DNA; ENTEROCYTES; ETOPOSIDE; FECES; FEMALE; HUMANS; INFANT; INTERLEUKIN-8; INTESTINAL ABSORPTION; LEUKEMIA, MYELOID; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MITOXANTRONE; MODELS, BIOLOGICAL; MUCOSITIS; STOMATITIS;

EID: 70449698426     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22210     Document Type: Article

References (28)

1. Creutzig U, Zimmermann M, Reinhardt D, et al. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: Analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol 2004;22:4384-4393.
2. Creutzig U, Zimmermann M, Lehrnbecher T, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: Results of AML-BFM 98. J Clin Oncol 2006;24:4499-4506.
3. Rapoport AP, Miller Watelet LF, Linder T, et al. Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants. J Clin Oncol 1999;17:2446-2453.
4. Elting LS, Cooksley C, Chambers M, et al. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 2003;98:1531-1539.
5. Sonis ST, Oster G, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001;19:2201-2205.
6. Bellm LA, Epstein JB, Rose-Ped A, et al. Patient reports of complications of bone marrow transplantation. Support Care Cancer 2000;8:33-39.
7. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer 2004;4:277-284.
8. National Cancer Institute [homepage on the internet]. Bethesda: U.S. National Institutes of Health; [updated 2006 Aug 9; cited 2008 Aug 8]. Cancer Therapy Evaluation Program; [about 1 screen]. Available from: http://ctep.cancer.gov/forms/CTCAEv3.pdf. 2006.
9. Gibson BES, Wheatley K, Hann IM, et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 2005;19:2130-2138.
10. Donnelly JP, Muus P, Schattenberg A, et al. A scheme for daily monitoring of oral mucositis in allogeneic BMT recipients. Bone Marrow Transplant 1992;9:409-413.
11. Blijlevens NM, van't Land B, Donnelly JP, et al. Measuring mucosal damage induced by cytotoxic therapy. Support Care Cancer 2004;12:227-233.
12. Oude Nijhuis C, Kamps WA, Daenen SM, et al. Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. J Clin Oncol 2005;23:7437-7444.
13. Bunn SK, Bisset WM, Main MJ, et al. Fecal calprotectin: Validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001;33:14-22.
14. Blijlevens NM, Lutgens LC, Schattenberg AV, et al. Citrulline: A potentially simple quantitative marker of intestinal epithelial damage following myeloablative therapy. Bone Marrow Transplant 2004;34:193-196.
15. Casellas F, Antolin M, Varela E, et al. Fecal excretion of human deoxyribonucleic acid as an index of inflammatory activity in ulcerative colitis. Clin Gastroenterol Hepatol 2004;2:683-689.
16. Casellas F, Borruel N, Antolin M, et al. Fecal excretion of deoxyribonucleic acid in long-term follow-up of patients with inactive ulcerative colitis. Inflamm Bowel Dis 2007;13:386-390.
17. Crenn P, Coudray-Lucas C, Thuillier F, et al. Postabsorptive plasma citrulline concentration is a marker of absorptive enterocyte mass and intestinal failure in humans. Gastroenterology 2000;119:1496-1505.
18. Lutgens LC, Blijlevens NM, Deutz NE, et al. Monitoring myeloablative therapy-induced small bowel toxicity by serum citrulline concentration: A comparison with sugar permeability tests. Cancer 2005;103:191-199.
19. Melichar B, Dvorak J, Krcmova L, et al. Intestinal permeability and vitamin A absorption in patients with chemotherapy-induced diarrhea. Am J Clin Oncol 2008;31:580-584.
20. van Eijk HM, Rooyakkers DR, Deutz NE. Rapid routine determination of amino acids in plasma by high-performance liquid chromatography with a 2-3 microns Spherisorb ODS II column. J Chromatogr 1993;620:143-148.
21. McBride C, Gaupp D, Phinney DG. Quantifying levels of transplanted murine and human mesenchymal stem cells in vivo by real-time PCR. Cytotherapy 2003;5:7-18.
22. Nadkarni MA, Martin FE, Jacques NA, et al. Determination of bacterial load by real-time PCR using a broad-range (universal) probe and primers set. Microbiology 2002;148:257-266.
23. Jansen G, Muskiet FA, Schierbeek H, et al. Capillary gas chromatographic profiling of urinary, plasma and erythrocyte sugars and polyols as their trimethylsilyl derivatives, preceded by a simple and rapid prepurification method. Clin Chim Acta 1986;157:277-293.
24. Crenn P, Vahedi K, Lavergne-Slove A, et al. Plasma citrulline: A marker of enterocyte mass in villous atrophy-associated small bowel disease. Gastroenterology 2003;124:1210-1219.
25. Blijlevens NM, Donnelly JP, DePauw BE. Inflammatory response to mucosal barrier injury after myeloablative therapy in allogeneic stem cell transplant recipients. Bone Marrow Transplant 2005;36:703-707.
26. Lutgens LC, Deutz N, Granzier-Peeters M, et al. Plasma citrulline concentration: A surrogate end point for radiation-induced mucosal atrophy of the small bowel. A feasibility study in 23 patients. Int J Radiat Oncol Biol Phys 2004;60:275-285.
27. Aadland E, Fagerhol MK. Faecal calprotectin: A marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol 2002;14:823-825.
28. Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis 2006;12:524-534.